博雅生物(300294)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300294 博雅生物

已收盘 06-03 15:00:00

{"stockData":{"symbol":"300294","market":"SZ","secType":"STK","nameCN":"博雅生物","latestPrice":16.77,"timestamp":1780470189000,"preClose":16.79,"halted":0,"volume":10598287,"delay":0,"changeRate":-0.0012,"floatShares":504000000,"shares":504000000,"eps":0.0069,"marketStatus":"已收盘","change":-0.02,"latestTime":"06-03 15:00:00","open":16.71,"high":17.1,"low":16.3,"amount":177000000,"amplitude":0.0476,"askPrice":16.78,"askSize":5,"bidPrice":16.77,"bidSize":38,"shortable":0,"etf":0,"ttmEps":0.0069,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1780536600000},"marketStatusCode":5,"adr":0,"adjPreClose":16.79,"symbolType":"stock","openAndCloseTimeList":[[1780450200000,1780457400000],[1780462800000,1780470000000]],"highLimit":18.47,"lowLimit":15.11,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":504248738,"isCdr":false,"pbRate":1.13,"roa":"--","peRate":2430.434783,"roe":"0.41%","epsLYR":0.22,"committee":-0.256367,"marketValue":8456000000,"turnoverRate":0.021,"status":1,"floatMarketCap":8456000000},"requestUrl":"/m/hq/s/300294/tweets","defaultTab":"tweets","newsList":[{"id":"2640167729","title":"博雅生物：2026 年一季度，公司采浆业务有序推进，采浆规模同比保持稳健增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2640167729","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640167729?lang=zh_cn&edition=full","pubTime":"2026-06-02 17:09","pubTimestamp":1780391346,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物(300294)06月02日在投资者关系平台上答复投资者关心的问题。投资者提问：您好：博雅生物2026年第一季采液量是多少啊博雅生物回复：您好，感谢您对本公司的关注。2026 年一季度，公司采浆业务有序推进，采浆规模同比保持稳健增长。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060200032423.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","300294","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640916742","title":"博雅生物：公司生产经营情况稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=2640916742","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640916742?lang=zh_cn&edition=full","pubTime":"2026-06-02 17:09","pubTimestamp":1780391345,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物(300294)06月02日在投资者关系平台上答复投资者关心的问题。投资者提问：近90天国际竞品价格是否有上涨？上涨幅度是多少？博雅生物回复：您好，感谢您对本公司的关注。公司生产经营情况稳定，产品价格随市场供需变化等情况产生波动。公司根据市场环境变化制定相应的价格策略。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060200032422.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300294","BK0239","BK0046","BK0197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640691629","title":"博雅生物：坚持长期主义，聚焦主业，提升经营质量与盈利能力","url":"https://stock-news.laohu8.com/highlight/detail?id=2640691629","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640691629?lang=zh_cn&edition=full","pubTime":"2026-06-02 17:06","pubTimestamp":1780391176,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物06月02日在投资者关系平台上答复投资者关心的问题。投资者提问：根据公开市场信息估算，截至2025年5月，华润医药持有博雅生物的综合加权平均持仓成本约为34.20元/股。公司一直坚持长期主义，紧紧围绕战略目标，聚焦主业，强化核心竞争力，结合政策环境、市场环境等制定适合公司发展的经营策略，努力做好经营管理，提升经营质量与盈利能力，促进公司健康可持续发展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060200032163.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","300294","BK0197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640868029","title":"股市必读：博雅生物（300294）5月29日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2640868029","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640868029?lang=zh_cn&edition=full","pubTime":"2026-06-01 04:40","pubTimestamp":1780260021,"startTime":"0","endTime":"0","summary":"截至2026年5月29日收盘，博雅生物报收于16.49元，上涨7.15%，换手率3.81%，成交量19.2万手，成交额3.15亿元。董秘最新回复投资者： 请问管理层血制品拐点何时到来？当日关注点来自交易信息汇总：5月29日主力资金净流入162.47万元，游资积极介入，散户资金呈净流出态势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060100001975.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300294","BK0046","BK0197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639762584","title":"博雅生物：今年公司产品尚未在巴西销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2639762584","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639762584?lang=zh_cn&edition=full","pubTime":"2026-05-29 17:11","pubTimestamp":1780045887,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物(300294)05月29日在投资者关系平台上答复投资者关心的问题。投资者提问：国外血制品除了人血白蛋白其他产品价格远远高于国内，请问董秘博雅生物是否有对巴西的血制品销售？金额有多少？博雅生物回复：您好，感谢您对本公司的关注。今年公司产品尚未在巴西销售。公司充分评估国际血液制品市场机会，持续推进产品国际注册事宜。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052900031650.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159100","BK0239","BK0046","BK0197","300294"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639562383","title":"博雅生物涨7.15%，开源证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2639562383","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639562383?lang=zh_cn&edition=full","pubTime":"2026-05-29 16:54","pubTimestamp":1780044886,"startTime":"0","endTime":"0","summary":"今日博雅生物涨7.15%，收盘报16.49元。2026年4月28日，开源证券研究员余汝意,阮帅发布了对博雅生物的研报《公司信息更新报告：2025年营收稳健增长，静待行业周期性复苏》，该研报对博雅生物给出“买入”评级。研报中预计公司2026-2028年归母净利润为2.41/2.77/3.53亿元，当前股价对应PE为37.5/32.7/25.6倍，考虑控股股东增持及华润赋能、公司估值性价比高，维持“买入”评级。博雅生物个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052900030644.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300294","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639961588","title":"股市必读：博雅生物（300294）5月28日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2639961588","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639961588?lang=zh_cn&edition=full","pubTime":"2026-05-29 03:23","pubTimestamp":1779996239,"startTime":"0","endTime":"0","summary":"截至2026年5月28日收盘，博雅生物报收于15.39元，上涨0.46%，换手率1.08%，成交量5.43万手，成交额8360.89万元。董秘最新回复投资者： 博雅生物高浓度静丙目前产能、销售、市占率如何？该产品在产品质量、病毒安全性等方面有显著的提高。当日关注点来自交易信息汇总：5月28日主力资金净流入121.03万元，显示主力对博雅生物当日交易持积极态度。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052900004712.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300294","BK0046","BK0197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638544447","title":"股市必读：博雅生物（300294）5月26日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2638544447","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638544447?lang=zh_cn&edition=full","pubTime":"2026-05-27 02:18","pubTimestamp":1779819493,"startTime":"0","endTime":"0","summary":"截至2026年5月26日收盘，博雅生物报收于15.61元，下跌1.2%，换手率0.91%，成交量4.57万手，成交额7148.36万元。董秘最新回复投资者： 公司股价越来越低，公司为什么不考虑回购增持？投资者： 结合博雅生物5年来的走势，请董秘简短评价一下博雅生物的《“质量回报双提升”行动方案》成果董秘： 您好，感谢您对本公司的关注与鞭策。公司兼顾经营发展与股东回报，2025年度现金分红总额占归属于上市公司股东净利润的99.78%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052700001917.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300294","BK0197","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638901355","title":"博雅生物：公司始终聚焦主业发展，不断优化浆站运营体系，采浆规模稳步提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2638901355","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638901355?lang=zh_cn&edition=full","pubTime":"2026-05-26 17:27","pubTimestamp":1779787625,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物05月26日在投资者关系平台上答复投资者关心的问题。研发工作有序开展，多款产品取得阶段性审批成果，海外产品注册亦获得积极进展。公司兼顾经营发展与股东回报，2025年度现金分红总额占归属于上市公司股东净利润的99.78%。后续公司将继续深耕主业、严控品质、提质增效，稳步推进各项战略落地，助力企业实现高质量发展。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052600029508.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","300294","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638597565","title":"博雅生物：持续深耕血液制品主业","url":"https://stock-news.laohu8.com/highlight/detail?id=2638597565","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638597565?lang=zh_cn&edition=full","pubTime":"2026-05-26 16:57","pubTimestamp":1779785842,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物(300294)05月26日在投资者关系平台上答复投资者关心的问题。投资者提问：请问管理层税率从3%到13%、渠道收窄零售终端增量被掐断、医保控费等问题，博雅生物出路在哪里？研发和产品推广有何改变？博雅生物回复：您好，感谢您对本公司的关注。公司将始终围绕战略目标，持续深耕血液制品主业，多措并举夯实发展根基，聚焦血浆、营销、研发、国际化等核心业务领域，持续蓄力厚植增长动能，提升综合竞争力。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052600028236.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0239","300294","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638302415","title":"股市必读：博雅生物（300294）5月22日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2638302415","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638302415?lang=zh_cn&edition=full","pubTime":"2026-05-25 03:14","pubTimestamp":1779650052,"startTime":"0","endTime":"0","summary":"截至2026年5月22日收盘，博雅生物报收于15.67元，下跌2.18%，换手率1.31%，成交量6.58万手，成交额1.03亿元。董秘最新回复投资者： 请问贵公司是否有意向将博雅打包出售给国药或者莱士？经查询中国证券登记结算有限责任公司的数据，公司2026年5月20日含信用账户合并名册的股东人数为31,639户。截至目前，公司暂无相关事项。如有，公司将根据证券法规及时履行信息披露义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052500001333.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0046","300294","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637392583","title":"博雅生物：公司2026年5月20日含信用账户合并名册的股东人数为31,639户","url":"https://stock-news.laohu8.com/highlight/detail?id=2637392583","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637392583?lang=zh_cn&edition=full","pubTime":"2026-05-22 16:42","pubTimestamp":1779439339,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物(300294)05月22日在投资者关系平台上答复投资者关心的问题。投资者提问：你好，截止5月20日，公司股东数量是多少？博雅生物回复：您好，感谢您对本公司的关注。经查询中国证券登记结算有限责任公司的数据，公司2026年5月20日含信用账户合并名册的股东人数为31,639户。以上内容为证券之星据公开信息整理，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052200030277.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0046","BK0239","300294"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637392509","title":"博雅生物：成为世界一流血液制品企业","url":"https://stock-news.laohu8.com/highlight/detail?id=2637392509","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637392509?lang=zh_cn&edition=full","pubTime":"2026-05-22 16:42","pubTimestamp":1779439338,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物(300294)05月22日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵公司是否有意向将博雅打包出售给国药或者莱士？博雅生物回复：您好，感谢您对本公司的关注。公司系华润集团大健康板块的血液制品平台，始终坚持“成为世界一流血液制品企业”的战略目标。控股股东在战略管理、组织优化、人才引进、风险管理及政府资源的嫁接等各方面，给予了公司极大的支持与赋能，为公司长远、稳定发展奠定了坚实的基础。以上内容为证券之星据公开信息整理，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052200030276.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300294","BK0239","BK0046","BK0197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636166040","title":"股市必读：博雅生物（300294）5月15日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2636166040","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636166040?lang=zh_cn&edition=full","pubTime":"2026-05-18 03:53","pubTimestamp":1779047589,"startTime":"0","endTime":"0","summary":"截至2026年5月15日收盘，博雅生物报收于16.45元，下跌1.61%，换手率1.11%，成交量5.62万手，成交额9328.77万元。公司公告汇总关于公司董事暨副总裁辞任的公告华润博雅生物制药集团股份有限公司董事会于2026年5月15日收到董事、副总裁梁化成先生的书面《辞任报告》。截至公告披露日，梁化成先生未持有公司股份，不存在应履行而未履行的承诺事项，辞任报告自送达董事会之日起生效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051800001598.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0239","300294","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635747112","title":"股市必读：博雅生物（300294）今年截至5月14日累计跌幅已超25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635747112","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635747112?lang=zh_cn&edition=full","pubTime":"2026-05-15 02:23","pubTimestamp":1778782990,"startTime":"0","endTime":"0","summary":"截至2026年5月14日收盘，博雅生物报收于16.72元，下跌2.62%，换手率1.18%，成交量5.96万手，成交额1.01亿元。当日关注点来自交易信息汇总：博雅生物股价已连续6日下跌，当年累计跌幅达25.42%。交易信息汇总股价提醒5月14日博雅生物收盘报16.72元，跌2.62%，当日成交595.71万元。资金流向5月14日主力资金净流出1347.51万元；游资资金净流入10.59万元；散户资金净流入1336.92万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051500001904.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0197","BK0046","300294"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635733159","title":"博雅生物（300294）披露变更办公地址及投资者联系电话公告，5月13日股价下跌1.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635733159","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635733159?lang=zh_cn&edition=full","pubTime":"2026-05-13 22:23","pubTimestamp":1778682197,"startTime":"0","endTime":"0","summary":"截至2026年5月13日收盘，博雅生物报收于17.17元，较前一交易日下跌1.72%，最新总市值为86.58亿元。该股当日开盘17.53元，最高17.54元，最低17.1元，成交额达1.05亿元，换手率为1.2%。近日，华润博雅生物制药集团股份有限公司发布《关于变更办公地址及投资者联系电话的公告》。上述变更自公告发布之日起生效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051300045684.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","300294","BK0197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635787564","title":"博雅生物：外延式并购存在较大不确定性","url":"https://stock-news.laohu8.com/highlight/detail?id=2635787564","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635787564?lang=zh_cn&edition=full","pubTime":"2026-05-13 20:51","pubTimestamp":1778676687,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物(300294)05月12日在投资者关系平台上答复投资者关心的问题。投资者提问：请问管理层今年有定增收购血制品企业打算吗博雅生物回复：您好，感谢您对本公司的关注。公司始终关注行业发展趋势，并聚焦有利于提升公司核心竞争力、创造长期价值的战略机会，但外延式并购存在较大不确定性。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051300042410.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","BK0197","300294"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634629619","title":"博雅生物：静注人免疫球蛋白（pH4）具有免疫替代和免疫调节的双重治疗作用","url":"https://stock-news.laohu8.com/highlight/detail?id=2634629619","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634629619?lang=zh_cn&edition=full","pubTime":"2026-05-12 16:21","pubTimestamp":1778574075,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物05月12日在投资者关系平台上答复投资者关心的问题。公司主营业务为生产和销售血液制品，主要产品为人血白蛋白、静注人免疫球蛋白、特异性免疫球蛋白、凝血因子类产品等。公司生产的免疫球蛋白类产品多用于免疫性疾病治疗，传染性疾病被动免疫和治疗等。其中静注人免疫球蛋白主要用于原发性免疫球蛋白缺乏症、继发性免疫球蛋白缺陷病、自身免疫性疾病。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051200026892.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300294","BK0197","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634864426","title":"股市必读：博雅生物（300294）5月8日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2634864426","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634864426?lang=zh_cn&edition=full","pubTime":"2026-05-11 02:40","pubTimestamp":1778438423,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘，博雅生物报收于17.73元，上涨2.01%，换手率1.37%，成交量6.93万手，成交额1.23亿元。董秘最新回复投资者： 请问董秘，公司是否计划定增介绍下。截至目前，公司暂无筹划及推进中的定增计划。公司公告汇总公司关于参加江西辖区上市公司2026年投资者网上集体接待日活动的公告华润博雅生物制药集团股份有限公司将参加由江西省上市公司协会举办的“2026年江西辖区上市公司投资者网上集体接待日活动”。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100001273.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300294","BK0197","BK0239","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634494719","title":"博雅生物：持续深耕血液制品主业","url":"https://stock-news.laohu8.com/highlight/detail?id=2634494719","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634494719?lang=zh_cn&edition=full","pubTime":"2026-05-09 14:15","pubTimestamp":1778307311,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物05月09日在投资者关系平台上答复投资者关心的问题。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050900006730.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0046","300294","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1780485212820,"stockEarnings":[{"period":"1week","weight":0.0756},{"period":"1month","weight":-0.0352},{"period":"3month","weight":-0.1852},{"period":"6month","weight":-0.2792},{"period":"1year","weight":-0.3671},{"period":"ytd","weight":-0.2537}],"compareEarnings":[{"period":"1week","weight":-0.017},{"period":"1month","weight":-0.009},{"period":"3month","weight":-0.0018},{"period":"6month","weight":0.0514},{"period":"1year","weight":0.2174},{"period":"ytd","weight":0.0268}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"华润博雅生物制药集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"31639人(较上一季度减少0.41%)","perCapita":"15937股","listingDate":"2012-03-08","address":"江西省抚州市临川区高新技术产业开发区惠泉路333号","registeredCapital":"50424万元","survey":"　　华润博雅生物制药集团股份有限公司的主营业务是血液制品的研发、生产和销售。公司的主要产品是人血白蛋白、人免疫球蛋白、静注人免疫球蛋白（含10%高浓度剂型）、冻干静注人免疫球蛋白、乙肝人免疫球蛋白、破伤风免疫球蛋白、狂犬病人免疫球蛋白、人纤维蛋白原、人凝血酶原复合物、人凝血因子Ⅷ。公司技术实力雄厚，先后承担了国家“863计划”项目、江西省重大研发专项等20多项政府专项，拥有各类专利200余项，多次荣膺省、市科学技术奖和优秀新产品奖。","listedPrice":25},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"博雅生物(300294)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供博雅生物(300294)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"博雅生物,300294,博雅生物股票,博雅生物股票老虎,博雅生物股票老虎国际,博雅生物行情,博雅生物股票行情,博雅生物股价,博雅生物股市,博雅生物股票价格,博雅生物股票交易,博雅生物股票购买,博雅生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"博雅生物(300294)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供博雅生物(300294)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}